Pharmaceutical giants Novartis Bristol Myers halt trials of their competing experimental cell therapies aimed at treating autoimmune disorders, following three patient deaths linked to a severe, potentially life threatening immune reaction observed during testing.
Novartis paused eight separate trials of its experimental therapy, known as rap-cel, after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare but serious condition in which the body’s immune defenses turn against its own organs.
The affected trials had been testing the cell therapy across a range of autoimmune and neurological conditions, including lupus, rheumatoid arthritis, vasculitis, multiple sclerosis, and myasthenia gravis. More than five hundred patients had already enrolled across these paused studies before the halt was implemented.
Bristol Myers Squibb, developing a competing cell therapy called zola-cel for similar autoimmune conditions, voluntarily paused its own trials as a precautionary measure after detecting temporary and reversible inflammatory events during routine safety monitoring, though the company reported no fatalities within its own program.
Both companies are part of a broader wave of pharmaceutical research exploring whether cell therapies originally developed to treat certain blood cancers might also prove effective against various autoimmune conditions, an area of significant scientific interest and substantial industry investment in recent years.
The specific immune reaction responsible for these deaths represents a recognized, though uncommon, risk associated with this type of cell therapy technology. It occurs when engineered immune cells introduced during treatment expand rapidly within the body, triggering an overwhelming and dangerous inflammatory response.
Novartis has described this reaction as a known risk of the underlying technology, emphasizing that the company is conducting a comprehensive review of the deaths while actively sharing information with relevant health regulatory authorities throughout the ongoing investigation process.
Two separate Novartis trials evaluating the same underlying therapy for blood cancers rather than autoimmune conditions were not included in the pause, suggesting the specific risk profile may vary depending on the particular patient population and underlying disease being treated with the cell therapy.
Industry analysts note that safety setbacks like this one, while serious, are not entirely unexpected given the experimental and relatively novel nature of applying cell therapy technology to autoimmune conditions, an application area still considered scientifically and clinically new compared to established cancer treatment protocols.
Patient advocacy groups have expressed concern about the deaths while also acknowledging the importance of thorough safety review processes, noting that identifying and understanding serious adverse events remains a critical function of the clinical trial system, even when it results in difficult setbacks for promising research.
As both companies conduct their respective safety reviews, the broader implications for autoimmune cell therapy research remain uncertain. Regulatory decisions stemming from these investigations could significantly influence how other companies pursuing similar therapeutic approaches proceed with their own autoimmune focused development programs going forward.
